Close

Macrogenics (MGNX) Announces Federica O'Brien to Board

Go back to Macrogenics (MGNX) Announces Federica O'Brien to Board

MacroGenics Names Federica O’Brien to its Board of Directors

February 11, 2021 4:30 PM EST

ROCKVILLE, MD, Feb. 11, 2021 (GLOBE NEWSWIRE) --  MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced the appointment of Federica Freddi OBrien, President of CFOBrien Consulting, LLC, to its Board of Directors.

Federica OBrien is a veteran executive with 25 years of financial and operational leadership in biopharmaceutical, medical device, and technology companies and currently serves on the Board of Directors of TELA Bio, Inc. where she also chairs the Audit Committee. Ms. OBrien will be joining MacroGenics Audit Committee.

"We... More